Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) announce they have entered into a definitive merger agreement under which Paratek will acquire Optinose, including its approved product XHANCE® (fluticasone propionate). The transaction value is up to $330 million, with consideration payable to shareholders of up to $14 per share, including the payment of contingent value rights (CVRs) tied to future commercial milestones. This acquisition expands Paratek’s commercial portfolio beyond its flagship antibiotic, NUZYRA® (omadacycline), and strengthens its position as a multi-product company focused on innovative specialty therapies for primary care providers and specialists, addressing important medical health threats.
Read the full article: Paratek Pharmaceuticals to Acquire Optinose //
Source: https://www.globenewswire.com/news-release/2025/03/20/3045908/0/en/Paratek-Pharmaceuticals-to-Acquire-Optinose-Creating-Significant-Commercial-Expansion-Opportunities-for-XHANCE-in-Chronic-Rhinosinusitis-CRS.html